ReviewJournal of orthopaedics2025
The effects of continuing aspirin and clopidogrel on perioperative outcomes in primary elective total knee and hip replacement: A systematic review and meta-analysis.
Review in Journal of orthopaedics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Approximately 20 % of patients undergoing primary elective total hip (THR) or knee replacement (TKR) take an antiplatelet medication. The two main management strategies are continuing or discontinuing the antiplatelet medication pre-operatively. Continuing antiplatelets may increase the risk of bleeding, wound complications, and infection. Discontinuing antiplatelets may increase the risk of cardiac and cerebrovascular adverse events. This systematic review and meta-analysis evaluated the effects of continuing aspirin or clopidogrel on the perioperative outcomes of patients undergoing THR or TKR. Methods: Medline, Embase, Web of Science, and Cochrane Library were searched for randomised controlled trials and cohort studies reporting on outcomes blood loss, infection, wound complications, operative duration, length of stay, venous thromboembolism, cardiac and cerebrovascular events, mortality, and others. Random effects meta-analysis was performed. Results: Eight studies enabled inclusion of data on 928 THRs and 3526 TKRs. Continuing antiplatelet therapy did not affect intraoperative blood loss in THR (MD -16.57 ml, 95 % CI -120.75-87.61, p = 0.76) or TKR (MD -0.06 ml, 95 %CI -6.04-5.91, p = 0.98). However, TKR patients continuing antiplatelet therapy had a higher risk of blood transfusion (OR 1.63, 95 %CI 1.25-2.13, p = 0.0003) although there were no differences observed in THR patients (OR 1.71, 95 %CI 0.84-3.49, p = 0.14). No significant differences were found for outcomes infection, cardiac and cerebrovascular events, and post-operative mortality between patient groups following THR and TKR. Conclusions: Continuing antiplatelet use during TKR, but not THR, was associated with an increased risk of blood transfusion. Surgical complications and medical adverse events were not influenced by antiplatelet use. Further research with larger sample sizes is needed to draw definitive conclusions.PROSPERO (CRD42024470601).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.